Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in ...
Phase 3 BOND-003 study results highlight cretostimogene monotherapy's efficacy in high-risk BCG-unresponsive NMIBC, showing a 75.2% complete response rate and durable responses over 12 months. With no Grade 3+ TRAEs, it offers a bladder-sparing option, potentially improving patient outcomes and quality of life.
Related Clinical Trials
Reference News
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in ...
Phase 3 BOND-003 study results highlight cretostimogene monotherapy's efficacy in high-risk BCG-unresponsive NMIBC, showing a 75.2% complete response rate and durable responses over 12 months. With no Grade 3+ TRAEs, it offers a bladder-sparing option, potentially improving patient outcomes and quality of life.